Antibody Response and Safety of a Novel Recombinant Zona Pellucida Vaccine Formulation in Mares
This study aimed to assess serum anti-ZP antibody response and safety following administration of novel ZP-based formulations to horse mares. Mares (n=31) were subdivided into age-categorised (6y) treatment groups for active immunisation with either: porcine ZP proteins (pZP; University of Pretoria, South Africa) (n=7; 2 treatments), novel recombinant ZP proteins (reZP; CSIR, South Africa) (n=8; 3 treatments) or combined pZP and reZP proteins (n=8; 2 treatments).
Source: Journal of Equine Veterinary Science - Category: Veterinary Research Authors: M.B. Nolan, H.J. Bertschinger, M.L. Schulman Source Type: research
More News: African Health | Science | South Africa Health | Study | Vaccines | Veterinary Research | Veterinary Vaccinations